journal
MENU ▼
Read by QxMD icon Read
search

Leukemia Research

journal
https://www.readbyqxmd.com/read/27923195/aplastic-anemia-and-mds-international-foundation-aamdsif-bone-marrow-failure-disease-scientific-symposium-2016
#1
Amer M Zeidan, Minoo Battiwalla, Deborah Berlyne, Thomas Winkler
Patients with acquired and inherited bone marrow failure syndromes (BMFS) have ineffective hematopoiesis due to impairments of the hematopoietic stem cell compartment. Common manifestations of BMFS include varying degrees of peripheral blood cytopenias and, sometimes, progression to acute myelogenous leukemia. Research efforts have been made all over the world to improve understanding of the pathogenesis of these diseases and their clinical implications. The Aplastic Anemia and MDS International Foundation (AAMDSIF) is an independent nonprofit organization whose mission is to help patients and family members cope with BMFS...
November 24, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27884397/corrigendum-to-bcl11a-expression-in-acute-phase-chronic-myeloid-leukemia-leuk-res-47-2016-88-92
#2
Jiawei Yin, Fan Zhang, Huiquan Tao, Xiao Ma, Guangsong Su, Xiaoli Xie, Zhongjuan Xu, Yanwen Zheng, Hong Liu, Chao He, Zhengwei Jenny Mao, Zhiwei Wang, Weirong Chang, Robert Peter Gale, Depei Wu, Bin Yin
No abstract text is available yet for this article.
November 21, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27889686/microrna-181-contributes-to-downregulation-of-samhd1-expression-in-cd4-t-cells-derived-from-s%C3%A3-zary-syndrome-patients
#3
Rebecca Kohnken, Karthik M Kodigepalli, Anjali Mishra, Pierluigi Porcu, Li Wu
Sézary syndrome (SS) is a rare subtype of cutaneous T-cell lymphoma (CTCL) that is characterized by aggressive spread of neoplastic CD4+ T-cells from the skin into the bloodstream with metastasis to visceral organs. The deoxynucleoside triphosphohydrolase SAMHD1 is highly expressed in normal CD4+ T-cells, while its expression is down-regulated in CD4+ T-cells from SS patients. MicroRNA (miR) dysregulation is an important epigenetic mechanism in the pathogenesis and progression of SS. MiR-181 has been shown to inhibit SAMHD1 expression in cell lines and was identified as an important prognostic biomarker in CTCL...
November 17, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27883945/recent-advances-in-the-treatment-of-lower-risk-non-del-5q-myelodysplastic-syndromes-mds
#4
REVIEW
Antonio Almeida, Pierre Fenaux, Alan F List, Azra Raza, Uwe Platzbecker, Valeria Santini
Patients with lower-risk myelodysplastic syndromes (MDS) are affected primarily by symptoms of chronic anemia and fatigue rather than progression to acute myeloid leukemia. Severe thrombocytopenia, although less common in lower-risk MDS, is associated with increased risk of bleeding. For anemic patients, the principal aim of treatment is to improve anemia and decrease red blood cell transfusions. For transfusion-dependent patients with lower-risk MDS without chromosome 5q deletion [non-del(5q) MDS], there are limited effective treatments...
November 13, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27875783/prame-overexpression-predicted-good-outcome-in-pediatric-b-cell-acute-lymphoblastic-leukemia-patients-receiving-chemotherapy
#5
Yan-Huan Zhang, Ai-Dong Lu, Lu Yang, Ling-Di Li, Wen-Min Chen, Ling-Yu Long, Le-Ping Zhang, Ya-Zhen Qin
To investigate the prognostic value of PRAME expression in pediatric acute lymphoblastic leukemia(ALL), we measured PRAME transcript levels at diagnosis in 191 patients(146 B-ALL; 45T-ALL)receiving chemotherapy only. PRAME overexpression was defined as transcript levels higher than 0.30%, which is the upper limit of normal bone marrow and the optimal cutoff value derived from ROC curve analysis. PRAME overexpression was identified in 45.5% of patients. In B-ALL, PRAME overexpression was significantly associated with lower CIR(cumulative incidence of relapse), higher DFS (disease-freesurvival), and OS(overall survival) rates at 3 years, respectively (5...
November 11, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27870947/subcellular-localization-of-the-flt3-itd-oncogene-plays-a-significant-role-in-the-production-of-nox-and-p22-phox-derived-reactive-oxygen-species-in-acute-myeloid-leukemia
#6
Jennifer N Moloney, Joanna Stanicka, Thomas G Cotter
Internal tandem duplication of the juxtamembrane domain of FMS-like tyrosine kinase 3 (FLT3-ITD) receptor is the most prevalent FLT3 mutation accounting for 20% of acute myeloid leukemia (AML) patients. FLT3-ITD mutation results in ligand-independent constitutive activation of the receptor at the plasma membrane and 'impaired trafficking' of the receptor in compartments of the endomembrane system, such as the endoplasmic reticulum (ER). FLT3-ITD expressing cells have been shown to generate increased levels of reactive oxygen species (ROS), in particular NADPH oxidase (NOX)-generated ROS which act as pro-survival signals...
November 11, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27870946/conserved-hierarchical-gain-of-chromosome-4-is-an-independent-prognostic-factor-in-high-hyperdiploid-pediatric-acute-lymphoblastic-leukemia
#7
Á Vojcek, G Pajor, D Alpár, R Mátics, L Pótó, K Szuhai, L Pajor
BACKGROUND: High hyperdiploid (HeH) pre-B pediatric acute lymphoblastic leukemia (B-pALL) is known to be heterogeneous by prognosis, but the stratification principals according to conventional cytogenetic analysis (CCA) are equivocal. PROCEDURE: Untreated bone marrow samples of 214 B-pALL patients were previously classified according to the modal numbers (iMN8) based on the gains of the chromosomes 4, 6, 10, 14, 17, 18, 21, and X as revealed by consecutive and correlated 2×4 color interphase fluorescence in situ hybridization, and at least five years of follow up data were analyzed...
November 11, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27855285/computational-drug-treatment-simulations-on-projections-of-dysregulated-protein-networks-derived-from-the-myelodysplastic-mutanome-match-clinical-response-in-patients
#8
Leylah Drusbosky, Cindy Medina, Regina Martuscello, Kimberly E Hawkins, Myron Chang, Jatinder K Lamba, Shireen Vali, Ansu Kumar, Neeraj Kumar Singh, Taher Abbasi, Mikkael A Sekeres, Mar Mallo, Francesc Sole, Rafael Bejar, Christopher R Cogle
Although the majority of MDS patients fail to achieve clinical improvement to approved therapies, some patients benefit from treatment. Predicting patient response prior to therapy would improve treatment effectiveness, avoid treatment-related adverse events and reduce healthcare costs. Three separate cohorts of MDS patients were used to simulate drug response to lenalidomide alone, hypomethylating agent (HMA) alone, or HMA plus lenalidomide. Utilizing a computational biology program, genomic abnormalities in each patient were used to create an intracellular pathway map that was then used to screen for drug response...
November 6, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27855286/casiopeina-iii-ea-a-copper-containing-small-molecule-inhibits-the-in-vitro-growth-of-primitive-hematopoietic-cells-from-chronic-myeloid-leukemia
#9
Antonieta Chavez-Gonzalez, Sandra Centeno-Llanos, Dafne Moreno-Lorenzana, Miguel Angel Sandoval-Esquivel, Socrates Aviles-Vazquez, María Elena Bravo-Gomez, Lena Ruiz-Azuara, Manuel Ayala-Sanchez, Hector Torres-Martinez, Hector Mayani
Several novel compounds have been developed for the treatment of different types of leukemia. In the present study, we have assessed the in vitro effects of Casiopeina III-Ea, a copper-containing small molecule, on cells from patients with Chronic Myeloid Leukemia (CML). We included primary CD34(+) Lineage-negative (Lin(-)) cells selected from CML bone marrow, as well as the K562 and MEG01 cell lines. Bone marrow cells obtained from normal individuals - both total mononuclear cells as well as CD34(+) Lin(-) cells- were used as controls...
November 3, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27870945/erythropoietin-administration-is-associated-with-improved-t-cell-properties-in-patients-with-myelodysplastic-syndromes
#10
Naamit Deshet-Unger, Howard S Oster, Sara Prutchi-Sagiv, Nir Maaravi, Nataliya Golishevski, Drorit Neumann, Moshe Mittelman
The immune system is impaired in myelodysplastic syndromes (MDS) and plays a role in the pathogenesis of the disease. Here we show effects of recombinant human erythropoietin (rHuEPO) on T cell (CD4(+), CD8(+) and CD4(+)CD25(+)) number and function in MDS patients. Healthy (20 subjects), MDS patients without rHuEPO treatment ('MDS', 13), and MDS patients treated with rHuEPO ('MDS+EPO', 17) were examined. CD4(+) and CD8(+) T cell numbers were reduced and increased respectively in MDS compared to healthy subjects...
November 2, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27855324/green-tea-polyphenol-epigallocatechin-3-gallate-differentially-induces-apoptosis-in-cll-b-and-t-cells-but-not-in-healthy-b-and-t-cells-in-a-dose-dependant-manner
#11
Scott Cornwall, Gavin Cull, David Joske, Reza Ghassemifar
B-cell chronic lymphocytic leukaemia (CLL) is characterized by an accumulation of CD5-positive monoclonal B-cells due in large part to a failure of apoptosis. The ability to study CLL B-cells in vitro has always been a challenge and hampered by the low viability of the CLL B-cells in cell culture systems. In this study, we present a multicellular cell culture system to maintain CLL B-cells viable in culture for 60h in the presence of a stromal cell feeder layer in combination with a whole white blood cell preparation...
November 2, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27846431/increased-tim3-cd8-t-cells-in-myelodysplastic-syndrome-patients-displayed-less-perforin-and-granzyme-b-secretion-and-higher-cd95-expression
#12
Jinglian Tao, Lijuan Li, Yingshuai Wang, Rong Fu, Huaquan Wang, Zonghong Shao
T cell immunoglobulin and mucin domain 3(TIM3) is a negative regulator of cellular immunity and it is highly expressed on CD8+T cells in persistent viral infection and cancer setting as report. However, how TIM3 expressed on CD8+T cells in myelodysplastic syndrome (MDS), that is a malignant disorder, has not been clarified. Here, decreased CD8+T cells, less IFN-γ secretion in CD8+T cells and increased TIM3 on CD8+T cells had been seen. Increased TIM3+CD8+T cells with lower perforin and granzyme B expression and higher CD95 expression in MDS patients had been observed...
November 2, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27776290/good-riddance-to-the-term-refractory-anemia-in-myelodysplastic-syndromes
#13
David P Steensma
The term "refractory anemia" was used in 1937 by Cornelius Parker Rhoads to describe patients whose anemia did not improve after treatment with liver extract or iron salts, and this term has been used to denote patients with certain subtypes of myelodysplastic syndromes (MDS) since the 1976 and 1982 French-American-British (FAB) classifications of acute leukemias and MDS. In 2016, the World Health Organization (WHO) proposed elimination of "refractory anemia" in a more general proposal for reclassification of myeloid neoplasia...
October 17, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27776289/why-do-subjects-on-clinical-trials-discontinue-therapy-do-we-really-know
#14
Bruno C Medeiros, Robert Peter Gale
No abstract text is available yet for this article.
October 17, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27770655/low-abcb1-and-high-oct1-levels-play-a-favorable-role-in-the-molecular-response-to-imatinib-in-cml-patients-in-the-community-clinical-practice
#15
Flavia da Cunha Vasconcelos, Marcos Antonio Mauricio Scheiner, Arthur Moellman-Coelho, André Luiz Mencalha, Ilana Zalcberg Renault, Vivian Mary Rumjanek, Raquel Ciuvalschi Maia
Despite the favorable clinical evolution of patients with chronic myeloid leukemia (CML), resistance or intolerance to imatinib is present in approximately 35% of patients. Sokal score is a widely used risk factor, however efflux and influx transporters are provisional risk factors implicated in imatinib resistance. This study analyzed Sokal score, ABCB1, ABCG2 and OCT1 mRNA transporter expression levels as well as P-glycoprotein expression and efflux transporters activity to seek a possible correlation between these factors and the molecular response at 12 months from imatinib start as well as 8-year overall survival (OS)...
October 12, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27769008/myelodysplastic-syndromes-aiming-at-deciphering-their-secrets
#16
Michael D Diamantidis, Daphne Papanastasiou
No abstract text is available yet for this article.
October 12, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27736728/differential-expression-and-response-to-arsenic-stress-of-mrps-and-asan1-determine-sensitivity-of-classical-multidrug-resistant-leukemia-cells-to-arsenic-trioxide
#17
Jing Chen, Jie Cheng, Juan Yi, Bei Xie, Li Lin, Zhuan Liu, Huaishun Zhao, Bei Wang, Ziying Ai, Yue Yang, Hulai Wei
There is no cross-resistance between arsenic trioxide and conventional chemotherapeutics. Classical multi-drug resistant (MDR) cells remain sensitive to arsenic trioxide, which may even reverse the drug resistance. Arsenic trioxide is also effective in leukemias/tumors that persist despite conventional cytotoxic or targeted drugs. We obtained a highly arsenic-resistant MDR leukemic cell line, HL-60/RS, by exposing leukemic HL-60 cells to adriamycin selection. We compared the arsenic sensitivity, and the expression and responses to arsenic of the arsenic-related transporters, MRP1, MRP2, and ASNA1, in paired parent/arsenic-resistant HL-60/RS/HL-60 and arsenic-sensitive/parental K562/ADM/K562 cells...
October 3, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27721163/deletion-5q-is-frequent-in-myelodysplastic-syndrome-mds-patients-diagnosed-with-interstitial-lung-diseases-ild-mayo-clinic-experience
#18
Rama Nanah, Darci Zblewski, Mrinal S Patnaik, Kebede Begna, Rhett Ketterling, Vivek N Iyer, William J Hogan, Mark R Litzow, Aref Al-Kali
A variety of interstitial Lung Diseases (ILD) have been described in patients with myelodysplastic syndromes (MDS) with possible etiologies including autoimmunity, drug related toxicity, and recurrent infections. A comprehensive study of ILD in MDS patients has not been previously performed. Out of 827 consecutive biopsy proven MDS patients seen at our institution from June 1970-May 2010, 18 (2%) were found to have ILD. There was no statistical significance in baseline characteristics between patients with ILD (ILD +) vs those without ILD (ILD-)...
October 3, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27736729/kb004-a-first-in-class-monoclonal-antibody-targeting-the-receptor-tyrosine-kinase-epha3-in-patients-with-advanced-hematologic-malignancies-results-from-a-phase-1-study
#19
Ronan T Swords, Peter L Greenberg, Andrew H Wei, Simon Durrant, Anjali S Advani, Mark S Hertzberg, Ian D Lewis, Gabriel Rivera, Dita Gratzinger, Alice C Fan, Dean W Felsher, Jorge E Cortes, Justin M Watts, Geoff T Yarranton, Jackie M Walling, Jeffrey E Lancet
EphA3 is an Ephrin receptor tyrosine kinase that is overexpressed in most hematologic malignancies. We performed a first-in-human multicenter phase I study of the anti-EphA3 monoclonal antibody KB004 in refractory hematologic malignancies in order to determine safety and tolerability, along with the secondary objectives of pharmacokinetics (PK) and pharmacodynamics (PD) assessments, as well as preliminary assessment of efficacy. Patients were enrolled on a dose escalation phase (DEP) initially, followed by a cohort expansion phase (CEP)...
September 28, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27710869/plasma-proteomics-in-cml-patients-before-and-after-initiation-of-tyrosine-kinase-inhibitor-therapy-reveals-induced-th1-immunity-and-loss-of-angiogenic-stimuli
#20
Stina Söderlund, Lisa Christiansson, Inger Persson, Henrik Hjorth-Hansen, Johan Richter, Bengt Simonsson, Satu Mustjoki, Ulla Olsson-Strömberg, Angelica Loskog
BACKGROUND AND AIMS: The simultaneous measurement of many proteins is now possible using multiplex assays. In this pilot study we investigated a total of 124 proteins in plasma from chronic myeloid leukemia (CML) patients with the purpose of identifying proteins that are differently expressed at diagnosis and after tyrosine kinase inhibitor (TKI) treatment initiation. METHODS: Samples were taken from 14 CML patients at diagnosis and after three months of TKI treatment (imatinib or dasatinib)...
September 27, 2016: Leukemia Research
journal
journal
27133
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"